Shilpa Biologicals, having its R&D and manufacturing facility in Dharwad, Karnataka, is a biologics manufacturing & services company focused on developing curative therapies with a cutting-edge team of scientists and committed professionals at the manufacturing floor.
Our product pipeline focuses on immunology, ophthalmology and hematology sectors with the goal of making it affordable to patients worldwide. Adalimumab is our first biosimilar launched in India and we are on the journey to file in regulatory markets this year.
Our services hail from the deep confidence in our scientific strength and ability to make a marked difference to high-level scientific breakthroughs happening across the world.
By leveraging our bedrocks in molecular biology, biochemistry, immunology, and formulations, we have built a robust pipeline of wholly owned projects that have the potential to revolutionize the blood-product segment and compete globally for the best-in-class services.
Today, our company comprises of talented professionals who strive in giving their bests for the welfare of patients worldwide. Our scientists have the innovation capable to disrupt the status-quo in thinking new-age solutions to deep scientific problems.
